<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">J Cancer</journal-id><journal-id journal-id-type="publisher-id">jca</journal-id><journal-title-group><journal-title>Journal of Cancer</journal-title></journal-title-group><issn pub-type="epub">1837-9664</issn><publisher><publisher-name>Ivyspring International Publisher</publisher-name><publisher-loc>Sydney</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11786044</article-id><article-id pub-id-type="doi">10.7150/jca.105586</article-id><article-id pub-id-type="publisher-id">jcav16p1167</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Integrating of Radiomics and Single-cell Transcriptomics Uncovers the Crucial Role of &#x003b3;&#x003b4; T Cells in Lung Adenocarcinoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Ziyi</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="FNA_dagger" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Changqing</given-names></name><xref rid="A4" ref-type="aff">4</xref><xref rid="FNA_dagger" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jiajing</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="FNA_dagger" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Baichuan</given-names></name><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Long</given-names></name><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Zhaoyi</given-names></name><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yingxi</given-names></name><xref rid="A7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name><surname>Qin</surname><given-names>Tingting</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="FNA_envelop" ref-type="corresp">&#x02709;</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Peng</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="FNA_envelop" ref-type="corresp">&#x02709;</xref></contrib></contrib-group><aff id="A1"><label>1</label>Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.</aff><aff id="A2"><label>2</label>Tianjin's Clinical Research Center for Cancer, Tianjin, China.</aff><aff id="A3"><label>3</label>Department of Thoracic Oncology, Tianjin Lung Cancer Center, Tianjin Cancer Institute &#x00026; Hospital, Tianjin Medical University, Tianjin, 300060, PR China</aff><aff id="A4"><label>4</label>Respiratory Department, Tianjin Medical University General Hospital, Tianjin 300052, China.</aff><aff id="A5"><label>5</label>Anhui Chest Hospital, Anhui Medical University Clinical College of Chest, Hefei, Anhui Province, 23002, China.</aff><aff id="A6"><label>6</label>Department of General Surgery, Tianjin Medical University General Hospital, Tianjin Key Laboratory of Precise Vascular Reconstruction and Organ Function Repair, Tianjin General Surgery Institute, Tianjin, 300052, China.</aff><aff id="A7"><label>7</label>Immunology Department, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Tianjin Medical University, Tianjin, 300070, China.</aff><author-notes><corresp id="FNA_envelop">&#x02709; Corresponding authors: Prof Peng Chen, Department of Thoracic Oncology, Tianjin Lung Cancer Center, Tianjin Cancer Institute &#x00026; Hospital, Tianjin Medical University, Tianjin, 300060, PR China, E-mail: <email>chenpeng@tjmuch.com</email>. Prof Tingting Qing, Department of Thoracic Oncology, Tianjin Lung Cancer Center, Tianjin Cancer Institute &#x00026; Hospital, Tianjin Medical University, Tianjin, 300060, PR China, E-mail: <email>qintingting@tjmuch.com</email>.</corresp><fn fn-type="equal" id="FNA_dagger"><p><sup>&#x02020;</sup> These authors contributed equally to this work.</p></fn><fn fn-type="COI-statement"><p>Competing Interests: The authors have declared that no competing interest exists.</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>6</day><month>1</month><year>2025</year></pub-date><volume>16</volume><issue>4</issue><fpage>1167</fpage><lpage>1180</lpage><history><date date-type="received"><day>21</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>23</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The author(s)</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>). See <ext-link ext-link-type="uri" xlink:href="https://ivyspring.com/terms">https://ivyspring.com/terms</ext-link> for full terms and conditions.</license-p></license></permissions><abstract><p>Gamma-delta (&#x003b3;&#x003b4;) T cells are a crucial component of the tumor immune microenvironment which are considered a promising potential therapeutic strategy and target. Increasing evidence suggests that these unique immune cells play significant roles across various cancers. However, &#x003b3;&#x003b4; T cells are often regarded as having dual roles in tumors, and their influence on lung adenocarcinoma (LUAD) remains controversial. In this research, we employed a wild-ranging approach using multi-omics data to investigate the function of &#x003b3;&#x003b4; T cells in LUAD. The abundance of &#x003b3;&#x003b4; T cell infiltration is linked to a positive prognosis in lung adenocarcinoma. The tumor-inhibiting role of &#x003b3;&#x003b4; T cells was played through intrinsic lineage evolution, acquiring cytotoxic functions and engaging in signal transduction with antigen-presenting cells. Furthermore, patients with higher &#x003b3;&#x003b4; T cells infiltration abundance might be more favorable for immunotherapy. Lastly, we established a predictive model using CT images based on radiomics, providing a non-invasive strategy to assess &#x003b3;&#x003b4; T cells infiltration in LUAD patients. These findings offer new insights and perspectives the personalized therapies of &#x003b3;&#x003b4; T cells.</p></abstract><kwd-group><kwd>gamma-delta T cells</kwd><kwd>lung adenocarcinoma</kwd><kwd>tumor microenvironment</kwd><kwd>immunotherapy</kwd><kwd>radiomics</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>&#x003b3;&#x003b4; T cells represent an emerging field in tumor immunology, and their effects on the tumor microenvironment and therapeutic applications remain unclear compared to CD8+ and CD4+ T cells. In recent years, research related to &#x003b3;&#x003b4; T cells has attracted more and more attention in the academic community. &#x003b3;&#x003b4; T cells represent a distinct subset of infiltrating lymphocytes in the tumor microenvironment, possessing important and distinct functions and characteristics. Compared to the typical &#x003b1;&#x003b2; T cells, &#x003b3;&#x003b4; T cells possess a unique T cell receptor on their surface, which is constituted of both a &#x003b3; chain and a &#x003b4; chain<xref rid="B1" ref-type="bibr">1</xref>. Meanwhile, &#x003b3;&#x003b4; T cells have the ability to detect the early changes when normal cells transform into tumor cells and they can sense tumors even in the presence of low mutational burden, exhibiting a certain degree of sensitivity and a rapid response<xref rid="B1" ref-type="bibr">1</xref>. Notably, &#x003b3;&#x003b4; T cells possess multifaceted immune characteristics, as they not only directly kill tumor cells but also regulate immune function indirectly through the secretion of cytokines, such as IFN-&#x003b1; and TNF-&#x003b3; thereby activating other immune cells<xref rid="B2" ref-type="bibr">2</xref>. Currently, conventional immunotherapies primarily rely on alpha-beta T cells, which are strictly dependent on MHC molecules, substantially reducing the therapeutic effectiveness and usability in different situations<xref rid="B3" ref-type="bibr">3</xref>. In contrast, one of the key advantages of &#x003b3;&#x003b4; T cells is the MHC independence, allowing for allogeneic transplantation and they have been reported to be correlated with survival rates in multiple cancers, showing promising antitumor potential and application prospects<xref rid="B4" ref-type="bibr">4</xref>. The &#x003b3;&#x003b4; T cells possess unique clinical translational value and hold significant promise in cancer therapy. Nevertheless, there is still evidence indicating that &#x003b3;&#x003b4; T cells may promote tumorigenesis across various cancers. To give an example, Reis BS <italic>et al.</italic> discovered that &#x003b3;&#x003b4; T cells could exhibit effects of promoting tumor in colorectal cancers (CRCs)<xref rid="B5" ref-type="bibr">5</xref>. Similarly, there were reports that &#x003b3;&#x003b4; T cells may make a positive contribution in tumor growth in ovarian cancer<xref rid="B6" ref-type="bibr">6</xref>. Consequently, it is crucial to perform a detailed investigation of the function of &#x003b3;&#x003b4; T cells in particular cancer types.</p><p>Lung cancer has consistently ranked among the most prevalent and fatal malignancies worldwide<xref rid="B7" ref-type="bibr">7</xref>. Characterized by high incidence and mortality rates, lung cancer imposes a substantial burden on global healthcare systems<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>. More than 80% of all lung cancers are classified under the NSCLC, of which lung adenocarcinoma (LUAD) consists of the majority subtype<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>. The molecular heterogeneity within and between tumors has long posed a major obstacle in treating patients with lung adenocarcinoma<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>. Furthermore, issues such as drug resistance and metastasis have led to unsatisfactory prognoses for lung adenocarcinoma<xref rid="B14" ref-type="bibr">14</xref>. Thus, it is essential to discover new therapeutic targets and risk stratification strategies with clinical translational significance in lung adenocarcinoma against these challenges, ultimately benefiting a greater number of patients.</p><p>Single-cell RNA sequencing technology has made significant progress in recent years, providing a novel research perspective for further exploration of the tumor microenvironment<xref rid="B15" ref-type="bibr">15</xref>. The sc-RNA technology offers unique advantages in revealing the intra-tumoral heterogeneity and interactions among different cellular components<xref rid="B16" ref-type="bibr">16</xref>. Radiomics presents a clinical application method for disease assessment that is characterized by non-invasiveness, reproducibility and cost-effectiveness<xref rid="B17" ref-type="bibr">17</xref>. The integrated application of various technologies could better assist researchers in analyzing the properties of the TME.</p><p>In the UK project TRACERx of lung cancer, the researchers evaluated lung tumor tissues and adjacent cancerous samples from 25 individuals with NSCLC and found that &#x003b3;&#x003b4; T cells were indeed infiltrated in the tumor<xref rid="B18" ref-type="bibr">18</xref>. Nevertheless, the biological function of &#x003b3;&#x003b4; T cells in lung adenocarcinoma still remains controversial, and their specific function within this cancer type have seldom been explored through multi-omics profiling methods. Based on this fact, we employed multi-omics data, including sc-RNA sequencing data, bulk transcriptomic data, somatic mutation data, immune response data, and CT imaging radiomics data, to investigate the potential duty of &#x003b3;&#x003b4; T cells in the TME of LUAD.</p><p>We discovered that &#x003b3;&#x003b4; T cells in the TME of LUAD were associated with both favorable prognosis and downregulation of malignant pathways, and they might possess an intrinsic developmental trend that further enhances their direct cytotoxic function and immune regulatory roles. Notably, somatic mutations in genes such as Lipoprotein-A (<italic>LPA</italic>), Dynein Axonemal Heavy Chain 8 (<italic>DNAH8</italic>), and Tenascin N (<italic>TNN</italic>) may serve as driver genes that induce these differences. Furthermore, &#x003b3;&#x003b4; T cells were demonstrated to have closely connection with immune therapy. Additionally, we established a clinical application model to assess the infiltration levels of &#x003b3;&#x003b4; T cells through CT imaging. Overall, the further research to investigate the prognostic value of &#x003b3;&#x003b4; T cells in tumors and their potential as a key therapeutic strategy were crucial for patients with lung adenocarcinoma.</p></sec><sec sec-type="methods"><title>Materials and Methods</title><sec><title>Data collection and preliminary processing</title><p>The sc-RNA profile GSE223923 containing four samples from different lung adenocarcinoma patients utilized in the research was obtained from the Gene Expression Omnibus Series<xref rid="B19" ref-type="bibr">19</xref>. Bulk RNA transcriptome data, clinical data, and single nucleotide variant (SNV) data were gathered from the LUAD cohort of The Cancer Genome Atlas (TCGA, <ext-link xlink:href="https://portal.gdc.cancer.gov/" ext-link-type="uri">https://portal.gdc.cancer.gov/</ext-link>) via the 'TCGAbiolinks' package<xref rid="B20" ref-type="bibr">20</xref>. CT image data for radiomics were collected from The Cancer Imaging Archive (TCIA, <ext-link xlink:href="https://dev.cancerimagingarchive.net/" ext-link-type="uri">https://dev.cancerimagingarchive.net/</ext-link>)<xref rid="B21" ref-type="bibr">21</xref>. Single-cell RNA profiles were analyzed applying the Seurat (version 4.3.0) R package. Regular quality control (The QC standards can be found in detail in <xref rid="SM0" ref-type="sec">Supplementary Figure 1</xref>) was conducted on each scRNA sequencing data required and the software package DoubletFinder (version 2.0.3)<xref rid="B22" ref-type="bibr">22</xref> was employed to detect and filter potential cell doublets. Harmony (version 1.2.0)<xref rid="B23" ref-type="bibr">23</xref> was employed to eliminate batch effects and integrate information across different samples which could be found in <xref rid="SM0" ref-type="sec">Supplementary Figure 2</xref>. Sctransform (version 0.3.5)<xref rid="B24" ref-type="bibr">24</xref> was used for data normalization and removal of confounding sources of variation, such as mitochondrial interference percentage. Clustree (version 0.5.1)<xref rid="B25" ref-type="bibr">25</xref> was used to visualize the resolution for further selection.</p></sec><sec><title>Downstream analysis of single-cell RNA transcriptome data</title><p>The annotated biological markers for different cell populations were derived from the online database CellMarker 2.0<xref rid="B26" ref-type="bibr">26</xref> and previously published studies. Intrinsic spectral evolution and developmental trend of &#x003b3;&#x003b4; T were analyzed using monocle (version 2.26.0)<xref rid="B27" ref-type="bibr">27</xref> with 'DDRTree' being the default dimensionality reduction method and the max component was set to 2. Cell-to-cell communication analysis was performed with CellChat (version 1.6.1)<xref rid="B28" ref-type="bibr">28</xref> and call CellChatDB.human database for analysis. To estimate the infiltration abundance of &#x003b3;&#x003b4; T cells, we employed the CIBERSORTx platform<xref rid="B29" ref-type="bibr">29</xref> which is an analytical tool designed to deconvolute immune cell composition based on RNA-seq data. CIBERSORTx deconvolution algorithm could utilize a reference expression profile to calculate the relative fraction of &#x003b3;&#x003b4; T cells in absolute mode based on bulk sequence data.</p></sec><sec><title>Gene enrichment analysis</title><p>We utilized the limma package (version 3.58.1)<xref rid="B30" ref-type="bibr">30</xref> to identify the differential expression genes between the different &#x003b3;&#x003b4; T cell infiltration abundance groups, defining genes with a p &#x0003c; 0.05 as statistically significant and ranking them based on the log fold change (logFC) of their expression levels. Gene sets data were obtained from the Gene Set Enrichment Analysis (GSEA, <ext-link xlink:href="https://www.gsea-msigdb.org/gsea/index.jsp" ext-link-type="uri">https://www.gsea-msigdb.org/gsea/index.jsp</ext-link>) database<xref rid="B31" ref-type="bibr">31</xref>. The enrichment analysis results were visualized with the 'clusterProfiler' package (version 4.12.2)<xref rid="B32" ref-type="bibr">32</xref> and the 'GseaVis' package (version 0.0.5).</p></sec><sec><title>Somatic mutation landscape and survival analysis</title><p>The 'TCGAbiolinks' package was employed to retrieve the required single nucleotide variant (SNV) mutation data from the Cancer Genome Atlas (TCGA) database as mentioned above. Comprehensive analysis and visualization of masked somatic mutation profiles were conducted with the 'maftools'<xref rid="B33" ref-type="bibr">33</xref> package (version 2.20.0). Fisher's exact test was employed to recognize significant gene pairs between different groups. Survival prognostic analyses were achieved with the 'survminer' package (version 0.4.9) and p &#x0003c; 0.05 was defined as statistical significance.</p></sec><sec><title>Computerized estimation of treatment response to ICIs</title><p>The potential response of immune checkpoint inhibitors (ICIs) was assessed by TIDE algorithm. TIDE<xref rid="B34" ref-type="bibr">34</xref> was a tool based on tumor immune escape mechanism that integrates immune dysfunction and immune rejection features. To make the results as reliable as possible, the response scores of the different &#x003b3;&#x003b4; T cell infiltration abundance groups to immunotherapy were predicted using the EaSIeR package (version 1.10.0)<xref rid="B35" ref-type="bibr">35</xref> in combination with the responder data obtained from TIDE and the tumor mutation burden (TMB) data. The cell signature of the &#x003b3;&#x003b4; T cells population was calculated via the ssGSEA algorithm of the 'GSVA' package (version 1.50.5)<xref rid="B36" ref-type="bibr">36</xref> by top30-markers. The relationships between immunotherapeutic targets and signature score were investigated with Pearson correlation analysis.</p></sec><sec><title>Image segmentation, feature extraction and modelling for radiomics</title><p>The CT image data of 29 lung adenocarcinoma patients from The Cancer Imaging Archive (TCIA) with corresponding bulk transcriptome data was selected. The workflow was based on 3D Slicer software (version 5.6.2)<xref rid="B37" ref-type="bibr">37</xref> and its plugins. The process of region of interest (ROI) delineation and feature extraction adhered to the guidelines of The Image Biomarker Standardization Initiative<xref rid="B38" ref-type="bibr">38</xref>. Tumor regions were segmented by radiologists with over five years of experience, followed by review and confirmation by a senior clinician with over 20 years of experience. In cases of disagreement, an additional senior clinician was consulted for review. The Radiomics plugin was used to extract 851 radiomic features after the tumor regions were segmented layer by layer and reconstructed into three-dimensional images. To ensure uniform spacing resolution, all CT images were resampled into the same value during preprocessing. All extracted radiomic features underwent Z-score normalization. The correlation between the radiomics score and &#x003b3;&#x003b4; T cell infiltration abundance was conducted with Pearson correlation analysis. The 'glmnet' package (version 4.1-8)<xref rid="B39" ref-type="bibr">39</xref> was used with cross-validation to determine the best &#x003bb; value, and a least absolute shrinkage and selection operator (LASSO) regression model was developed to predict the infiltration abundance scores of &#x003b3;&#x003b4; T cells. Finally, the cohort was split into training and validation cohorts in a 2:1 ratio, and Pearson correlation was used to assess the model's performance.</p></sec><sec><title>Statistics</title><p>Relevant methods of statistical analyses are described above, and all statistical methods were analyzed by R (v 4.3.3).</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Identification of &#x003b3;&#x003b4; T cells in sc-RNA profile</title><p>As illustrated in Figure <xref rid="F1" ref-type="fig">1</xref>, this study intended to probe the existence of &#x003b3;&#x003b4;T cells in the TME of LUAD and their potential value in clinical application. The sc-RNA sequencing data from GSE223923 of LUAD-infiltrating immune cells isolated using PE-Cy7-conjugated CD45 antibody fluorescent dye from lung adenocarcinoma patients was selected for analysis to more precisely identify &#x003b3;&#x003b4; T cells. We then conducted an initial screening of the single-cell RNA profiles of the selected &#x003b3;&#x003b4;T cells. After removing potential doublets, the data quality and cell purity were deemed satisfactory. Following sequential batch effect removal and normalization processes, the cells were preliminarily classified into myeloid cells, endothelial cells, B cells, NK cells, plasma cells, epithelial cells and T cells. Further analysis divided the myeloid cells into neutrophils, monocytes, macrophages, pDCs, and mast cells. T cells were then subdivided into various subtypes, with a total of 1,818 &#x003b3;&#x003b4; T cells identified for subsequent analyses. UMAP and t-SNE methods were employed for dimensionality reduction and visualization (Figure <xref rid="F2" ref-type="fig">2</xref>A). Specifically, the annotation of &#x003b3;&#x003b4; T cells was further defined based on the expression levels of biological markers like <italic>TRDC</italic>, <italic>TRGC1</italic>, and <italic>TRGC2</italic>, with cell type annotation markers presented in Figure <xref rid="F2" ref-type="fig">2</xref>B.</p></sec><sec><title>&#x003b3;&#x003b4; T cells' cytotoxic and immunoregulatory roles via binary lineage evolution in the lung adenocarcinoma TME</title><p>To further elucidate the distribution and trajectory of &#x003b3;&#x003b4; T cells within the lung adenocarcinoma TME, pseudo-time analysis was conducted on the &#x003b3;&#x003b4; T cells and we discovered an inherent lineage evolution process. These cells exhibited a unique developmental and evolutionary trend (Figure <xref rid="F3" ref-type="fig">3</xref>A-B). Based on their temporal progression, we found that &#x003b3;&#x003b4;T cells could be divided into two distinct bioactive states. After correcting for batch effects, the cells could be artificially classified into GZMK- and <italic>GZMK+</italic> &#x003b3;&#x003b4;T cells, representing different developmental maturity and activity states, based on the changes in the expression of the cytotoxic marker gene <italic>GZMK</italic> (Figure <xref rid="F3" ref-type="fig">3</xref>C). Along the trajectory of cellular evolution in pseudo-time, the cells dynamically transitioned from <italic>GZMK-</italic> to <italic>GZMK+</italic>, with the expression of the lymphocyte chemokine-encoding genes <italic>XCL1</italic> (lymphotactin-1) and <italic>XCL2</italic> (lymphotactin-2) progressively increasing over time (Figure <xref rid="F3" ref-type="fig">3</xref>D). Thus, &#x003b3;&#x003b4; T cells demonstrated an inherent lineage development process that enhanced the immune functions within the lung adenocarcinoma TME. These cells exerted direct cytotoxic effects through the granzyme pathway and recruited additional immune cells via the lymphotactin pathway, thereby amplifying the anti-tumor immune response and modulating immune functions.</p></sec><sec><title>Intercellular communication between &#x003b3;&#x003b4; T cells and other cellular components in the TME of lung adenocarcinoma</title><p>Given the cell functions of &#x003b3;&#x003b4;T cells as a unique subtype of T cells, we had sufficient reasons to hypothesize that they might engage in potential intercellular communication with other cellular components in the tumor microenvironment, and that such interactions could be crucial for shaping the TME. Therefore, we conducted an in-depth investigation of the interaction network between &#x003b3;&#x003b4; T cells and other cells. We observed IFN-&#x003b3; signaling transmission between &#x003b3;&#x003b4; T cells and macrophages as well as monocytes, which suggested their active role in antigen presentation. Similarly, CD8+ tissue-resident memory T cells exhibited comparable signaling towards macrophages and monocytes, indicating a potential synergistic effect between CD8+ Trm cells and &#x003b3;&#x003b4; T cells in simultaneously activating these two cell types (Figure <xref rid="F3" ref-type="fig">3</xref>E). Furthermore, researchers found that &#x003b3;&#x003b4; T cells extensively transmitted signals to CD8+ T cells through human leukocyte antigen class I molecule pathways, thereby triggering cytotoxic responses as illustrated in Figure <xref rid="F3" ref-type="fig">3</xref>F. &#x003b3;&#x003b4; T cells also transmitted signals through <italic>HLA</italic> class II molecules to professional antigen-presenting cells (e.g., pDCs, monocytes, and macrophages) via pathways such as<italic> HLA-DRB1-CD4</italic>. This suggested that &#x003b3;&#x003b4;T cells may enhance tumor antigen presentation through these interactions, indirectly boosting the anti-tumor ability of CD4+ T cells. Notably, the <italic>CCL5-ACKR1</italic> pathway was significantly enriched in interactions from &#x003b3;&#x003b4;T cells to endothelial cells. These findings indicated that in addition to their direct cytotoxic effects, the indirect immunoregulatory functions of &#x003b3;&#x003b4;T cells were also an essential component.</p></sec><sec><title>Infiltration of &#x003b3;&#x003b4; T cells suggests favorable clinical prognosis</title><p>The trajectory evolution and immunoregulatory potential of &#x003b3;&#x003b4; T cells in the TME of LUAD had now been largely elucidated, prompting researchers to investigate whether high infiltration of &#x003b3;&#x003b4; T cells could be regard as a positive prognostic factor for patients. Therefore, we utilized the CIBERSORTx deconvolution algorithm to quantify the infiltration abundance of &#x003b3;&#x003b4; T cells in each patient and conducted survival analysis in the TCGA-LUAD cohort. Using the best cut-off value of infiltration abundance, patients were categorized into a high-infiltration group (N=84) and a low-infiltration group (N=419). The findings showed a statistically significant association between &#x003b3;&#x003b4; T cell infiltration and patient survival, with the high-infiltration group demonstrating better survival outcomes (p=0.011, Figure <xref rid="F4" ref-type="fig">4</xref>A). These findings suggested that the infiltration of &#x003b3;&#x003b4; T cells could be a positive guide for the prognostic assessment of LUAD patients.</p></sec><sec><title>Somatic mutation landscape with infiltration level of &#x003b3;&#x003b4; T cell</title><p>Be curious about whether somatic gene mutations in tumor cells could influence &#x003b3;&#x003b4; T cell infiltration, the somatic mutation landscape was conducted in different infiltration groups using the complete SNV data. After integrating the group data and excluding invalid entries, the Fisher's exact test was conducted to analyze significant differences in gene mutations between the two groups. Genes such as <italic>TNN</italic> (p&#x0003c;0.01) and <italic>DNAH9</italic> (p&#x0003c;0.05) showed higher somatic mutation frequencies in the high-infiltration group, whereas <italic>LPA</italic> (p&#x0003c;0.01), <italic>DNAH8</italic> (p&#x0003c;0.01), <italic>TIAM1</italic> (p&#x0003c;0.05), <italic>ASPM</italic> (p&#x0003c;0.05), and <italic>UNC5D</italic> (p&#x0003c;0.05) exhibited higher mutation frequencies in the low-infiltration abundance group (Figure <xref rid="F4" ref-type="fig">4</xref>B). Notably, <italic>TNN</italic> gene displayed more missense mutations in the high-infiltration abundance group, while <italic>DNAH9</italic> showed both more missense mutations and multi-hits in this group (Figure <xref rid="F4" ref-type="fig">4</xref>C). These results suggested significant differences in somatic mutations between patients with varying levels of &#x003b3;&#x003b4; T cell infiltration, indicating a nuanced association between &#x003b3;&#x003b4; T cell infiltration and somatic gene mutations.</p></sec><sec><title>High infiltration of &#x003b3;&#x003b4; T cells is correlated with the downregulation of malignant pathways</title><p>Building on the differential analysis of groups with different &#x003b3;&#x003b4; T cell infiltration abundance levels, we further investigated the potential mechanisms underlying these differences. After obtaining the list of differentially expressed genes using bulk transcriptome data, we ranked them by fold change and performed GSEA functional enrichment analysis to identify the molecular pathways potentially affected by &#x003b3;&#x003b4; T cell infiltration. Among the top 25 pathways in the GSEA analysis, we observed a marked downregulation of several tumor-associated malignant pathways as &#x003b3;&#x003b4; T cell infiltration increased. Specifically, the high &#x003b3;&#x003b4; T cell infiltration abundance group showed a downregulation of the <italic>KRAS</italic> signaling (NES = -1.47, adjusted p = 0.04), <italic>E2F</italic> targets (NES = -1.48, adjusted p = 0.01), G2M checkpoint (NES = -1.6, adjusted p &#x0003c; 0.001), <italic>Notch</italic> signaling (NES = -2.18, adjusted p &#x0003c; 0.001), TGF-&#x003b2; signaling (NES = -2.01, adjusted p &#x0003c; 0.01), and angiogenesis pathways (NES = -1.68, adjusted p = 0.03) (Figures <xref rid="F4" ref-type="fig">4</xref>D-I, Supplementary File: <xref rid="SM0" ref-type="sec">Table S1</xref>). Since <italic>KRAS</italic> is a well-recognized oncogene in the NSCLC, its inhibition could potentially reduce tumor progression. These findings indicate that &#x003b3;&#x003b4; T cells may inhibit tumor growth and metastasis by modulating various signaling pathways, including those involved in proliferation, immune response, and angiogenesis, thereby exerting anti-tumor effects.</p></sec><sec><title>Patients with higher &#x003b3;&#x003b4; T cell infiltration abundance derive more advantage from immunotherapy</title><p>Immunotherapy, especially immune checkpoint inhibitor therapy had revolutionized the treatment landscape for lung adenocarcinoma in recent years. Given the immunoregulatory function of &#x003b3;&#x003b4; T cells, we intended to analyze whether their infiltration could influence the response to immunotherapy. We observed that the high &#x003b3;&#x003b4; T cell infiltration abundance group had a greater number of responders to immunotherapy according to the TIDE results (p &#x0003c; 0.001, Figures <xref rid="F5" ref-type="fig">5</xref>A-B). Furthermore, high-infiltration group exhibited lower TIDE scores, suggesting a higher probability of receiving benefits from immunotherapy (p &#x0003c; 0.0043, Figure <xref rid="F5" ref-type="fig">5</xref>C). Additionally, we observed that patients in the high &#x003b3;&#x003b4; T cell infiltration group had higher EaSIeR algorithm scores combining TIDE responder result and TMB data, suggesting a more favorable immune microenvironment and a stronger response to immunotherapy (p &#x0003c; 0.027, Figure <xref rid="F5" ref-type="fig">5</xref>D). In our analysis of immune cells, we found that CD8+ T cells played a crucial role in the &#x003b3;&#x003b4; T cell-mediated response to immunotherapy (Figure <xref rid="F5" ref-type="fig">5</xref>E). Notably, the TRAIL pathway showed the strongest positive contribution to the immune response, suggesting it may be a potential pathway for &#x003b3;&#x003b4; T cell-mediated immunoregulation (Figure <xref rid="F5" ref-type="fig">5</xref>F). Applying the Seurat package, we identified the top 30 marker genes of &#x003b3;&#x003b4; T cells (p &#x0003c; 0.05) and converted them into a cell signature gene enrichment score matrix via ssGSEA. We discovered a positive correlation between the expression of &#x003b3;&#x003b4; T cell signatures and the immune checkpoint genes <italic>CTLA4</italic> (R = 0.64, p &#x0003c; 2.2e-16), <italic>LAG3</italic> (R = 0.68, p &#x0003c; 2.2e-16), <italic>PDCD1</italic> (R = 0.75, p &#x0003c; 2.2e-16), and <italic>CD274</italic> (R = 0.48, p &#x0003c; 2.2e-16) (Figures <xref rid="F5" ref-type="fig">5</xref>G-J) by Pearson correlation analysis. Therefore, the results mentioned above implied that patients with high &#x003b3;&#x003b4; T cell infiltration abundance might be better candidates for immunotherapy strategies.</p></sec><sec><title>&#x003b3;&#x003b4; T cells infiltration abundance can be measured using a radiomics model based on CT imaging</title><p>To further enhance the clinical translational value of this study, we established a non-invasive strategy to assess &#x003b3;&#x003b4; T cell infiltration levels, as illustrated in Figure <xref rid="F6" ref-type="fig">6</xref>A. We contained 29 LUAD patients from the TCIA database, and experienced oncologists manually delineated the regions of interest (ROIs) using 3D Slicer. These segmentations were then reviewed and refined by senior clinicians to precisely define the tumor areas and extract relevant feature values (Figure <xref rid="F6" ref-type="fig">6</xref>B). After extracting 851 features, we used Pearson correlation analysis to identify five features associated with &#x003b3;&#x003b4; T cell infiltration abundance. Further dimensionality reduction was performed using LASSO regression (Figure <xref rid="F6" ref-type="fig">6</xref>C-D), resulting in four radiomic features that were selected for constructing the final radiomics linear regression model, detailed in Supplementary File: <xref rid="SM0" ref-type="sec">Table S2</xref>. To assess the model's performance, we divided the cohort into a training set (n=20) and a validation set (n=9) using a 2:1 ratio and conducted correlation analysis. We discovered a positive correlation between the &#x003b3;&#x003b4; T cells infiltration and radiomics scores in both the training set (Figure <xref rid="F6" ref-type="fig">6</xref>E, R = 0.48, p = 0.034) and the validation set (Figure <xref rid="F6" ref-type="fig">6</xref>F, R = 0.72, p = 0.03). In conclusion, this study not only explored the function and significance of &#x003b3;&#x003b4; T cells in the TME of LUAD patients but also established an innovative and non-invasive method for predicting &#x003b3;&#x003b4; T cell infiltration abundance.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>In accordance with the existing reports, our study is the first to comprehensively clarify the role of &#x003b3;&#x003b4; T cells in the lung adenocarcinoma (LUAD) tumor microenvironment through the integration of multi-omics data. We perform a systematic and multi-layered analysis by integrating single-cell transcription, RNA-sequencing, radiomics, and genomics data. Our research comprehensively uncovered the infiltration of &#x003b3;&#x003b4; T cells within the TME of LUAD, including their intrinsic lineage evolution, their direct or indirect tumor-killing effects, their impact on immunotherapy, their association with radiomic features, and their cell-to-cell interactions.</p><p>The part played by &#x003b3;&#x003b4; T cells in lung adenocarcinoma remained controversial in previous studies. There were reports suggested that &#x003b3;&#x003b4; T cells not only served as a favorable prognostic marker in lung cancer but also exhibited stem cell-like characteristics, which might enable them to self-renew within the tumor. Furthermore, it was more likely for the patients with higher &#x003b3;&#x003b4; T cell infiltration abundance to respond to immunotherapy with pembrolizumab<xref rid="B18" ref-type="bibr">18</xref>. Clinical trials reported that immunotherapy with autologous &#x003b3;&#x003b4; T cells have shown to be secure and practicable in NSCLC, and for those patients who were resistant to other treatment, zoledronate-expanded &#x003b3;&#x003b4; T cells could represent a viable therapeutic option<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>. Moreover, studies have shown that immunotherapy of allogeneic &#x003b3;&#x003b4; T cell can extend the survival time of advanced lung cancer patients<xref rid="B42" ref-type="bibr">42</xref>. However, Jin C. <italic>et al.</italic> found that &#x003b3;&#x003b4; T cells could also promote the progression of lung adenocarcinoma through the mediation of commensal microbiota<xref rid="B43" ref-type="bibr">43</xref>. The potential pro-tumorigenic role of &#x003b3;&#x003b4; T cells is also a subject that warrants further investigation<xref rid="B44" ref-type="bibr">44</xref>. Research has demonstrated that &#x003b3;&#x003b4; T cells in the TME exhibit functional plasticity, engaging in dynamic interactions that toggle between anti- and pro-tumor activities, particularly &#x003b3;&#x003b4; T cells with the expression of IL-17, which may drive malignant phenotypes in tumors<xref rid="B3" ref-type="bibr">3</xref>. Given these findings, it is essential to integrate multi-omics data to further clarify the role of &#x003b3;&#x003b4; T cells in lung adenocarcinoma patients. This study employs a digital assessment strategy based on sc-RNA and bulk transcription data to quantify &#x003b3;&#x003b4; T cells infiltration abundance in the LUAD microenvironment, revealing that they play an overall positive role in tumor initiation, progression, prognosis, and treatment.</p><p>Even without addressing the factors influencing &#x003b3;&#x003b4; T cell infiltration abundance, our study remains exhaustive and compelling. &#x003b3;&#x003b4; T cells in the TME can exhibit a high degree of heterogeneity, with significant functional differences among different subtypes<xref rid="B45" ref-type="bibr">45</xref>. Our research identified an intrinsic lineage evolution of &#x003b3;&#x003b4; T cells in lung adenocarcinoma TME, where these cells tend to develop and mature towards the expression of <italic>GZMK</italic>,<italic> XCL1,</italic> and <italic>XCL2</italic>. <italic>GZMK</italic> (Granzyme K) as a serine protease of the granzyme family, is primarily expressed by cytotoxic T cells and natural killer (NK) cells, which is characterized by its cytotoxic properties<xref rid="B46" ref-type="bibr">46</xref>. Therefore, based on the expression of <italic>GZMK</italic> and its developmental trajectory within the &#x003b3;&#x003b4; T cell population, we artificially defined them into two distinct subgroups: <italic>GZMK-</italic> and <italic>GZMK+</italic>. The <italic>GZMK+</italic> subset represents a more mature cell state with a tendency towards cytotoxic functionality. <italic>XCL1</italic> (lymphotactin1) and <italic>XCL2</italic> (lymphotactin2) both belong to the XC subfamily of chemokines, and they have an impact on regulating immune cell migration, promoting maturation and activation, thus boosting the immune system's response. Notably, NK cells are also capable of expressing various chemokines, including <italic>XCL1</italic><xref rid="B47" ref-type="bibr">47</xref>. Our study discovered that &#x003b3;&#x003b4; T cells may recruit additional immune cells through the secretion of chemokines, thereby indirectly modulating immune function. Dividing &#x003b3;&#x003b4; T cells into these two differentiated cellular states facilitates a more precise understanding of their critical role in LUAD. IFN-&#x003b3; is a key regulatory factor in the tumor microenvironment which exerts a broad spectrum of influence and could be considered as the "master regulator" of the immune microenvironment<xref rid="B48" ref-type="bibr">48</xref>. We observed that &#x003b3;&#x003b4; T cells transmit signals through the IFN-II (IFN-&#x003b3;) pathway to macrophages and monocytes. Notably, CD8 Trms (tissue-resident memory T cells) also exhibit strong signaling interactions with macrophages and monocytes via this pathway. We hypothesize that there may be a synergistic relationship between CD8 Trms and &#x003b3;&#x003b4; T cells. Additionally, it was observed that &#x003b3;&#x003b4; T cells have cell-to-cell signaling with professional antigen-presenting cells (APCs, e.g., pDCs, monocytes, and macrophages) via MHC-II molecules, thereby enhancing their antigen-presenting capabilities and regulating immune function. <italic>CCL5</italic> is a chemokine reported to recruit more immune cells<xref rid="B49" ref-type="bibr">49</xref>, while vascular endothelial <italic>ACKR1</italic> facilitates the translocation of chemokines across blood vessels<xref rid="B50" ref-type="bibr">50</xref>. We found that &#x003b3;&#x003b4; T cells significantly interact with endothelial cells via the <italic>CCL-ACKR1</italic> signaling pathway. Endothelial cells primarily constitute the vascular walls in the TME, suggesting that &#x003b3;&#x003b4; T cells may remodel the tumor microenvironment by recruiting immune cells and altering the permeability of endothelial cells. Using a digital deconvolution algorithm, we predicted that patients with higher &#x003b3;&#x003b4; T cell infiltration abundance have better prognoses. Additionally, through GSEA functional enrichment analysis, we discovered the association between the increasing &#x003b3;&#x003b4; T cell infiltration abundance and the downregulation of pathways such as <italic>KRAS</italic>,<italic> E2F</italic>, G2M checkpoint, <italic>Notch</italic>, TGF-&#x003b2;, and angiogenesis which are related to malignant tumor phenotypes<xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B52" ref-type="bibr">52</xref>. In conclusion, these findings highlight the critical role of &#x003b3;&#x003b4; T cells in the LUAD microenvironment.</p><p>Immunotherapy has gradually become the mainstream treatment for LUAD in recent years, prompting researchers to further explore the potential value of &#x003b3;&#x003b4; T cells in this context. We found that patients in the high infiltration group of &#x003b3;&#x003b4; T cells exhibited better responses to immunotherapy. The treatment process was found to be strongly correlated with the TRAIL and JAK-STAT pathways, with the TRAIL pathway known to induce cell death<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B54" ref-type="bibr">54</xref>, which may represent a potential mechanism of &#x003b3;&#x003b4; T cells to exert biological functions. Interestingly, the JAK-STAT pathway has been reported to be activated by IFN-&#x003b3;<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B56" ref-type="bibr">56</xref>, which aligns with our findings in CellChat. Moreover, the infiltration abundance was positively correlated with common immunotherapy targets such as <italic>CTLA4</italic>, <italic>LAG3</italic>, <italic>PDCD1</italic>, and <italic>CD274</italic>, indicating that these patients are more suitable for immunotherapy and have significant clinical value. Through somatic mutation analysis, we discovered that a high abundance of &#x003b3;&#x003b4; T cell infiltration in LUAD is associated with the <italic>TNN</italic> and <italic>DNAH8</italic> genes mutations, suggesting that these mutations may contribute to the increased infiltration of &#x003b3;&#x003b4; T cells. Reports on the <italic>TNN</italic> gene primarily focus on non-oncological diseases<xref rid="B57" ref-type="bibr">57</xref>, while studies on the <italic>DNAH8</italic> gene mainly center on male infertility<xref rid="B58" ref-type="bibr">58</xref>. Our research provides new insight into the study of these two genes.</p><p>Radiomics provides a convenient, cost-effective, reproducible, and non-invasive strategy for the clinical assessment of biological characteristics. In our research, we aimed to establish an innovative non-invasive method for evaluating the infiltration abundance of &#x003b3;&#x003b4; T cells to demonstrate its practical value. Despite the limitation of sample number, we ensured the accuracy of our data sources as much as possible. We employed LASSO to introduce an L1 regularization term, which helped to avoid multicollinearity and improve the model's predictive capability. Our research indicates that a radiomics model established based on CT imaging features can predict the infiltration abundance of &#x003b3;&#x003b4; T cells, meanwhile its correlation was explored in both the training and validation datasets. This represents a bold innovative attempt, and we hope it will lay the groundwork for further research.</p><p>It bears mentioning that this research is an exploratory investigation based on multi-omics data which has certain limitations. Even though we employed a comprehensive approach, the sample size of sc-RNA data may limit the generalizability of our findings. Similarly, the scarcity of imaging data presents challenges to the stability of our model. We plan to collect more sample to validate the universality of our model. Furthermore, the clinical significance and translational value of &#x003b3;&#x003b4; T cells require confirmation from multi-center large sample cohorts. Owing to the limited abundance of &#x003b3;&#x003b4; T cells and the difficulties of establishing animal models<xref rid="B59" ref-type="bibr">59</xref>, we anticipate difficulties and challenges in elucidating their molecular mechanisms. However, despite the need for further research validation, we are convinced that the assessment results of &#x003b3;&#x003b4; T cells are reliable based on our relatively comprehensive research process. By investigating the immunomodulatory and antitumor effects of &#x003b3;&#x003b4; T cells in the LUAD microenvironment, this study is expected to deepen our understanding of the unique mechanisms of &#x003b3;&#x003b4; T cells.</p></sec><sec id="SM0" sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="SM1" position="float" content-type="local-data"><caption><p>Supplementary figures.</p></caption><media xlink:href="jcav16p1167s1.pdf"/></supplementary-material><supplementary-material id="SM2" position="float" content-type="local-data"><caption><p>Supplementary table 1.</p></caption><media xlink:href="jcav16p1167s2.csv"/></supplementary-material><supplementary-material id="SM3" position="float" content-type="local-data"><caption><p>Supplementary table 2.</p></caption><media xlink:href="jcav16p1167s3.csv"/></supplementary-material></sec></body><back><ack><p>The authors would like to thank the GEO and TCGA databases for the availability of the data. The workflow was drawn by Figdraw.</p><sec><title>Funding</title><p>This study is supported in part by grants from National Natural Science Foundation of China [Grant No.82272686] and Tianjin Key Medical Discipline (Specialty) Construction Project [Grant No.TJYXZDXK-010A]</p></sec><sec sec-type="data-availability"><title>Availability of data and materials</title><p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article.</p></sec><sec><title>Author contributions</title><p>Ziyi Chen and Changqing Yang designed the study, conducted data collection, data processing, statistical analysis. Baichuan Wang, Long He, Zhaoyi Liu and Yingxi Li wrote the manuscript. Jiajing Wang interpreted the results and revised the manuscript. Peng Chen and Tingting Qing provided overall guidance for this work. All authors have read and approved the final manuscript.</p></sec><sec><title>Consent for publication</title><p>All authors have agreed to publish this manuscript.</p></sec></ack><glossary><title>Abbreviations</title><def-list><def-item><term id="GL1">LUAD</term><def><p>lung adenocarcinoma</p></def></def-item><def-item><term id="GL2">IFN</term><def><p>interferon</p></def></def-item><def-item><term id="GL3">TNF</term><def><p>tumor necrosis factor</p></def></def-item><def-item><term id="GL4">TCGA</term><def><p>the cancer genome atlas program</p></def></def-item><def-item><term id="GL5">TCIA</term><def><p>the cancer imaging archive</p></def></def-item><def-item><term id="GL6">GEO</term><def><p>gene expression omnibus</p></def></def-item><def-item><term id="GL7">LASSO</term><def><p>least absolute shrinkage and selection operator</p></def></def-item><def-item><term id="GL8">MHC</term><def><p>major histocompatibility complex</p></def></def-item><def-item><term id="GL9">NSCLC</term><def><p>non-small cell lung cancer</p></def></def-item><def-item><term id="GL10">TME</term><def><p>tumor microenvironment</p></def></def-item><def-item><term id="GL11">GSEA</term><def><p>gene set enrichment analysis</p></def></def-item><def-item><term id="GL12">SNV</term><def><p>single nucleotide variant</p></def></def-item><def-item><term id="GL13">TMB</term><def><p>tumor mutation burden</p></def></def-item><def-item><term id="GL14">ICIs</term><def><p>immune checkpoint inhibitors</p></def></def-item><def-item><term id="GL15">ROI</term><def><p>region of interest</p></def></def-item><def-item><term id="GL16">CT</term><def><p>computed tomography</p></def></def-item></def-list></glossary><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><name><surname>Sebestyen</surname><given-names>Z</given-names></name><name><surname>Prinz</surname><given-names>I</given-names></name><name><surname>Dechanet-Merville</surname><given-names>J</given-names></name><name><surname>Silva-Santos</surname><given-names>B</given-names></name><name><surname>Kuball</surname><given-names>J</given-names></name><article-title>Translating gammadelta (gammadelta) T cells and their receptors into cancer cell therapies</article-title><source>Nat Rev Drug Discov</source><year>2020</year><volume>19</volume><fpage>169</fpage><lpage>84</lpage>
<pub-id pub-id-type="pmid">31492944</pub-id>
</element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><name><surname>Wu</surname><given-names>YL</given-names></name><name><surname>Ding</surname><given-names>YP</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>LW</given-names></name><name><surname>Wei</surname><given-names>CH</given-names></name><name><surname>Minato</surname><given-names>N</given-names></name><etal/><article-title>gammadelta T cells and their potential for immunotherapy</article-title><source>Int J Biol Sci</source><year>2014</year><volume>10</volume><fpage>119</fpage><lpage>35</lpage>
<pub-id pub-id-type="pmid">24520210</pub-id>
</element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><name><surname>Mensurado</surname><given-names>S</given-names></name><name><surname>Blanco-Dominguez</surname><given-names>R</given-names></name><name><surname>Silva-Santos</surname><given-names>B</given-names></name><article-title>The emerging roles of gammadelta T cells in cancer immunotherapy</article-title><source>Nat Rev Clin Oncol</source><year>2023</year><volume>20</volume><fpage>178</fpage><lpage>91</lpage>
<pub-id pub-id-type="pmid">36624304</pub-id>
</element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><name><surname>Hayday</surname><given-names>A</given-names></name><name><surname>Dechanet-Merville</surname><given-names>J</given-names></name><name><surname>Rossjohn</surname><given-names>J</given-names></name><name><surname>Silva-Santos</surname><given-names>B</given-names></name><article-title>Cancer immunotherapy by gammadelta T cells</article-title><source>Science</source><year>2024</year><volume>386</volume><fpage>eabq7248</fpage>
<pub-id pub-id-type="pmid">39361750</pub-id>
</element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><name><surname>Reis</surname><given-names>BS</given-names></name><name><surname>Darcy</surname><given-names>PW</given-names></name><name><surname>Khan</surname><given-names>IZ</given-names></name><name><surname>Moon</surname><given-names>CS</given-names></name><name><surname>Kornberg</surname><given-names>AE</given-names></name><name><surname>Schneider</surname><given-names>VS</given-names></name><etal/><article-title>TCR-Vgammadelta usage distinguishes protumor from antitumor intestinal gammadelta T cell subsets</article-title><source>Science</source><year>2022</year><volume>377</volume><fpage>276</fpage><lpage>84</lpage>
<pub-id pub-id-type="pmid">35857588</pub-id>
</element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><name><surname>Rei</surname><given-names>M</given-names></name><name><surname>Goncalves-Sousa</surname><given-names>N</given-names></name><name><surname>Lanca</surname><given-names>T</given-names></name><name><surname>Thompson</surname><given-names>RG</given-names></name><name><surname>Mensurado</surname><given-names>S</given-names></name><name><surname>Balkwill</surname><given-names>FR</given-names></name><etal/><article-title>Murine CD27(-) Vgamma6(+) gammadelta T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages</article-title><source>Proc Natl Acad Sci U S A</source><year>2014</year><volume>111</volume><fpage>E3562</fpage><lpage>70</lpage>
<pub-id pub-id-type="pmid">25114209</pub-id>
</element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><name><surname>Leiter</surname><given-names>A</given-names></name><name><surname>Veluswamy</surname><given-names>RR</given-names></name><name><surname>Wisnivesky</surname><given-names>JP</given-names></name><article-title>The global burden of lung cancer: current status and future trends</article-title><source>Nat Rev Clin Oncol</source><year>2023</year><volume>20</volume><fpage>624</fpage><lpage>39</lpage>
<pub-id pub-id-type="pmid">37479810</pub-id>
</element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><etal/><article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2024</year><volume>74</volume><fpage>229</fpage><lpage>63</lpage>
<pub-id pub-id-type="pmid">38572751</pub-id>
</element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Giaquinto</surname><given-names>AN</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><article-title>Cancer statistics, 2024</article-title><source>CA Cancer J Clin</source><year>2024</year><volume>74</volume><fpage>12</fpage><lpage>49</lpage>
<pub-id pub-id-type="pmid">38230766</pub-id>
</element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><name><surname>Cronin</surname><given-names>KA</given-names></name><name><surname>Lake</surname><given-names>AJ</given-names></name><name><surname>Scott</surname><given-names>S</given-names></name><name><surname>Sherman</surname><given-names>RL</given-names></name><name><surname>Noone</surname><given-names>AM</given-names></name><name><surname>Howlader</surname><given-names>N</given-names></name><etal/><article-title>Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics</article-title><source>Cancer</source><year>2018</year><volume>124</volume><fpage>2785</fpage><lpage>800</lpage>
<pub-id pub-id-type="pmid">29786848</pub-id>
</element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><name><surname>Herbst</surname><given-names>RS</given-names></name><name><surname>Morgensztern</surname><given-names>D</given-names></name><name><surname>Boshoff</surname><given-names>C</given-names></name><article-title>The biology and management of non-small cell lung cancer</article-title><source>Nature</source><year>2018</year><volume>553</volume><fpage>446</fpage><lpage>54</lpage>
<pub-id pub-id-type="pmid">29364287</pub-id>
</element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><name><surname>Skoulidis</surname><given-names>F</given-names></name><name><surname>Heymach</surname><given-names>JV</given-names></name><article-title>Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy</article-title><source>Nat Rev Cancer</source><year>2019</year><volume>19</volume><fpage>495</fpage><lpage>509</lpage>
<pub-id pub-id-type="pmid">31406302</pub-id>
</element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><name><surname>de Sousa</surname><given-names>VML</given-names></name><name><surname>Carvalho</surname><given-names>L</given-names></name><article-title>Heterogeneity in Lung Cancer</article-title><source>Pathobiology</source><year>2018</year><volume>85</volume><fpage>96</fpage><lpage>107</lpage>
<pub-id pub-id-type="pmid">29635240</pub-id>
</element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>XR</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><article-title>Drug resistance related genes in lung adenocarcinoma predict patient prognosis and influence the tumor microenvironment</article-title><source>Sci Rep</source><year>2023</year><volume>13</volume><fpage>9682</fpage>
<pub-id pub-id-type="pmid">37322027</pub-id>
</element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Shi</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><etal/><article-title>Identification of the tumor metastasis-related tumor subgroups overexpressed NENF in triple-negative breast cancer by single-cell transcriptomics</article-title><source>Cancer Cell Int</source><year>2024</year><volume>24</volume><fpage>319</fpage>
<pub-id pub-id-type="pmid">39294690</pub-id>
</element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Lei</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><etal/><article-title>Single-cell RNA-sequencing reveals radiochemotherapy-induced innate immune activation and MHC-II upregulation in cervical cancer</article-title><source>Signal Transduct Target Ther</source><year>2023</year><volume>8</volume><fpage>44</fpage>
<pub-id pub-id-type="pmid">36710358</pub-id>
</element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Copley</surname><given-names>SJ</given-names></name><name><surname>Viola</surname><given-names>P</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Aboagye</surname><given-names>EO</given-names></name><article-title>Radiomics and artificial intelligence for precision medicine in lung cancer treatment</article-title><source>Semin Cancer Biol</source><year>2023</year><volume>93</volume><fpage>97</fpage><lpage>113</lpage>
<pub-id pub-id-type="pmid">37211292</pub-id>
</element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Biswas</surname><given-names>D</given-names></name><name><surname>Usaite</surname><given-names>I</given-names></name><name><surname>Angelova</surname><given-names>M</given-names></name><name><surname>Boeing</surname><given-names>S</given-names></name><name><surname>Karasaki</surname><given-names>T</given-names></name><etal/><article-title>A local human Vdelta1 T cell population is associated with survival in nonsmall-cell lung cancer</article-title><source>Nat Cancer</source><year>2022</year><volume>3</volume><fpage>696</fpage><lpage>709</lpage>
<pub-id pub-id-type="pmid">35637401</pub-id>
</element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><name><surname>Mitsuhashi</surname><given-names>A</given-names></name><name><surname>Koyama</surname><given-names>K</given-names></name><name><surname>Ogino</surname><given-names>H</given-names></name><name><surname>Afroj</surname><given-names>T</given-names></name><name><surname>Nguyen</surname><given-names>NT</given-names></name><name><surname>Yoneda</surname><given-names>H</given-names></name><etal/><article-title>Identification of fibrocyte cluster in tumors reveals the role in antitumor immunity by PD-L1 blockade</article-title><source>Cell Rep</source><year>2023</year><volume>42</volume><fpage>112162</fpage>
<pub-id pub-id-type="pmid">36870329</pub-id>
</element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><name><surname>Colaprico</surname><given-names>A</given-names></name><name><surname>Silva</surname><given-names>TC</given-names></name><name><surname>Olsen</surname><given-names>C</given-names></name><name><surname>Garofano</surname><given-names>L</given-names></name><name><surname>Cava</surname><given-names>C</given-names></name><name><surname>Garolini</surname><given-names>D</given-names></name><etal/><article-title>TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data</article-title><source>Nucleic Acids Res</source><year>2016</year><volume>44</volume><fpage>e71</fpage>
<pub-id pub-id-type="pmid">26704973</pub-id>
</element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><name><surname>Clark</surname><given-names>K</given-names></name><name><surname>Vendt</surname><given-names>B</given-names></name><name><surname>Smith</surname><given-names>K</given-names></name><name><surname>Freymann</surname><given-names>J</given-names></name><name><surname>Kirby</surname><given-names>J</given-names></name><name><surname>Koppel</surname><given-names>P</given-names></name><etal/><article-title>The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository</article-title><source>J Digit Imaging</source><year>2013</year><volume>26</volume><fpage>1045</fpage><lpage>57</lpage>
<pub-id pub-id-type="pmid">23884657</pub-id>
</element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><name><surname>McGinnis</surname><given-names>CS</given-names></name><name><surname>Murrow</surname><given-names>LM</given-names></name><name><surname>Gartner</surname><given-names>ZJ</given-names></name><article-title>DoubletFinder: Doublet Detection in Single-Cell RNA Sequencing Data Using Artificial Nearest Neighbors</article-title><source>Cell Syst</source><year>2019</year><volume>8</volume><fpage>329</fpage><lpage>37</lpage><comment>e4</comment>
<pub-id pub-id-type="pmid">30954475</pub-id>
</element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><name><surname>Korsunsky</surname><given-names>I</given-names></name><name><surname>Millard</surname><given-names>N</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Slowikowski</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Wei</surname><given-names>K</given-names></name><etal/><article-title>Fast, sensitive and accurate integration of single-cell data with Harmony</article-title><source>Nat Methods</source><year>2019</year><volume>16</volume><fpage>1289</fpage><lpage>96</lpage>
<pub-id pub-id-type="pmid">31740819</pub-id>
</element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><name><surname>Hafemeister</surname><given-names>C</given-names></name><name><surname>Satija</surname><given-names>R</given-names></name><article-title>Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression</article-title><source>Genome Biol</source><year>2019</year><volume>20</volume><fpage>296</fpage>
<pub-id pub-id-type="pmid">31870423</pub-id>
</element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><name><surname>Zappia</surname><given-names>L</given-names></name><name><surname>Oshlack</surname><given-names>A</given-names></name><article-title>Clustering trees: a visualization for evaluating clusterings at multiple resolutions</article-title><source>Gigascience</source><year>2018</year><volume>7</volume><fpage>giy083</fpage>
<pub-id pub-id-type="pmid">30010766</pub-id>
</element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Bai</surname><given-names>J</given-names></name><etal/><article-title>CellMarker 2.0: an updated database of manually curated cell markers in human/mouse and web tools based on scRNA-seq data</article-title><source>Nucleic Acids Res</source><year>2023</year><volume>51</volume><fpage>D870</fpage><lpage>D6</lpage>
<pub-id pub-id-type="pmid">36300619</pub-id>
</element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Cacchiarelli</surname><given-names>D</given-names></name><name><surname>Grimsby</surname><given-names>J</given-names></name><name><surname>Pokharel</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Morse</surname><given-names>M</given-names></name><etal/><article-title>The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells</article-title><source>Nat Biotechnol</source><year>2014</year><volume>32</volume><fpage>381</fpage><lpage>6</lpage>
<pub-id pub-id-type="pmid">24658644</pub-id>
</element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><name><surname>Jin</surname><given-names>S</given-names></name><name><surname>Guerrero-Juarez</surname><given-names>CF</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>I</given-names></name><name><surname>Ramos</surname><given-names>R</given-names></name><name><surname>Kuan</surname><given-names>CH</given-names></name><etal/><article-title>Inference and analysis of cell-cell communication using CellChat</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><fpage>1088</fpage>
<pub-id pub-id-type="pmid">33597522</pub-id>
</element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><name><surname>Newman</surname><given-names>AM</given-names></name><name><surname>Steen</surname><given-names>CB</given-names></name><name><surname>Liu</surname><given-names>CL</given-names></name><name><surname>Gentles</surname><given-names>AJ</given-names></name><name><surname>Chaudhuri</surname><given-names>AA</given-names></name><name><surname>Scherer</surname><given-names>F</given-names></name><etal/><article-title>Determining cell type abundance and expression from bulk tissues with digital cytometry</article-title><source>Nat Biotechnol</source><year>2019</year><volume>37</volume><fpage>773</fpage><lpage>82</lpage>
<pub-id pub-id-type="pmid">31061481</pub-id>
</element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><name><surname>Ritchie</surname><given-names>ME</given-names></name><name><surname>Phipson</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Law</surname><given-names>CW</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><etal/><article-title>limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title><source>Nucleic Acids Res</source><year>2015</year><volume>43</volume><fpage>e47</fpage>
<pub-id pub-id-type="pmid">25605792</pub-id>
</element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><etal/><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>Proc Natl Acad Sci U S A</source><year>2005</year><volume>102</volume><fpage>15545</fpage><lpage>50</lpage>
<pub-id pub-id-type="pmid">16199517</pub-id>
</element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>E</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>P</given-names></name><name><surname>Dai</surname><given-names>Z</given-names></name><etal/><article-title>clusterProfiler 4.0: A universal enrichment tool for interpreting omics data</article-title><source>Innovation (Camb)</source><year>2021</year><volume>2</volume><fpage>100141</fpage>
<pub-id pub-id-type="pmid">34557778</pub-id>
</element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><name><surname>Mayakonda</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>DC</given-names></name><name><surname>Assenov</surname><given-names>Y</given-names></name><name><surname>Plass</surname><given-names>C</given-names></name><name><surname>Koeffler</surname><given-names>HP</given-names></name><article-title>Maftools: efficient and comprehensive analysis of somatic variants in cancer</article-title><source>Genome Res</source><year>2018</year><volume>28</volume><fpage>1747</fpage><lpage>56</lpage>
<pub-id pub-id-type="pmid">30341162</pub-id>
</element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Wan</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>P</given-names></name><etal/><article-title>Large-scale public data reuse to model immunotherapy response and resistance</article-title><source>Genome Med</source><year>2020</year><volume>12</volume><fpage>21</fpage>
<pub-id pub-id-type="pmid">32102694</pub-id>
</element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><name><surname>Lapuente-Santana</surname><given-names>O</given-names></name><name><surname>van Genderen</surname><given-names>M</given-names></name><name><surname>Hilbers</surname><given-names>PAJ</given-names></name><name><surname>Finotello</surname><given-names>F</given-names></name><name><surname>Eduati</surname><given-names>F</given-names></name><article-title>Interpretable systems biomarkers predict response to immune-checkpoint inhibitors</article-title><source>Patterns (N Y)</source><year>2021</year><volume>2</volume><fpage>100293</fpage>
<pub-id pub-id-type="pmid">34430923</pub-id>
</element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><name><surname>Hanzelmann</surname><given-names>S</given-names></name><name><surname>Castelo</surname><given-names>R</given-names></name><name><surname>Guinney</surname><given-names>J</given-names></name><article-title>GSVA: gene set variation analysis for microarray and RNA-seq data</article-title><source>BMC Bioinformatics</source><year>2013</year><volume>14</volume><fpage>7</fpage>
<pub-id pub-id-type="pmid">23323831</pub-id>
</element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><name><surname>Fedorov</surname><given-names>A</given-names></name><name><surname>Beichel</surname><given-names>R</given-names></name><name><surname>Kalpathy-Cramer</surname><given-names>J</given-names></name><name><surname>Finet</surname><given-names>J</given-names></name><name><surname>Fillion-Robin</surname><given-names>JC</given-names></name><name><surname>Pujol</surname><given-names>S</given-names></name><etal/><article-title>3D Slicer as an image computing platform for the Quantitative Imaging Network</article-title><source>Magn Reson Imaging</source><year>2012</year><volume>30</volume><fpage>1323</fpage><lpage>41</lpage>
<pub-id pub-id-type="pmid">22770690</pub-id>
</element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><name><surname>Zwanenburg</surname><given-names>A</given-names></name><name><surname>Vallieres</surname><given-names>M</given-names></name><name><surname>Abdalah</surname><given-names>MA</given-names></name><name><surname>Aerts</surname><given-names>H</given-names></name><name><surname>Andrearczyk</surname><given-names>V</given-names></name><name><surname>Apte</surname><given-names>A</given-names></name><etal/><article-title>The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping</article-title><source>Radiology</source><year>2020</year><volume>295</volume><fpage>328</fpage><lpage>38</lpage>
<pub-id pub-id-type="pmid">32154773</pub-id>
</element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><name><surname>Friedman</surname><given-names>J</given-names></name><name><surname>Hastie</surname><given-names>T</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name><article-title>Regularization Paths for Generalized Linear Models via Coordinate Descent</article-title><source>J Stat Softw</source><year>2010</year><volume>33</volume><fpage>1</fpage><lpage>22</lpage>
<pub-id pub-id-type="pmid">20808728</pub-id>
</element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><name><surname>Nakajima</surname><given-names>J</given-names></name><name><surname>Murakawa</surname><given-names>T</given-names></name><name><surname>Fukami</surname><given-names>T</given-names></name><name><surname>Goto</surname><given-names>S</given-names></name><name><surname>Kaneko</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>Y</given-names></name><etal/><article-title>A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells</article-title><source>Eur J Cardiothorac Surg</source><year>2010</year><volume>37</volume><fpage>1191</fpage><lpage>7</lpage>
<pub-id pub-id-type="pmid">20137969</pub-id>
</element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><name><surname>Sakamoto</surname><given-names>M</given-names></name><name><surname>Nakajima</surname><given-names>J</given-names></name><name><surname>Murakawa</surname><given-names>T</given-names></name><name><surname>Fukami</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>Y</given-names></name><name><surname>Murayama</surname><given-names>T</given-names></name><etal/><article-title>Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded gammadeltaTcells: a phase I clinical study</article-title><source>J Immunother</source><year>2011</year><volume>34</volume><fpage>202</fpage><lpage>11</lpage>
<pub-id pub-id-type="pmid">21304399</pub-id>
</element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Xiang</surname><given-names>Z</given-names></name><name><surname>Alnaggar</surname><given-names>M</given-names></name><name><surname>Kouakanou</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>J</given-names></name><etal/><article-title>Allogeneic Vgamma9Vdelta2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer</article-title><source>Cell Mol Immunol</source><year>2021</year><volume>18</volume><fpage>427</fpage><lpage>39</lpage>
<pub-id pub-id-type="pmid">32939032</pub-id>
</element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><name><surname>Jin</surname><given-names>C</given-names></name><name><surname>Lagoudas</surname><given-names>GK</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Bullman</surname><given-names>S</given-names></name><name><surname>Bhutkar</surname><given-names>A</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><etal/><article-title>Commensal Microbiota Promote Lung Cancer Development via gammadelta T Cells</article-title><source>Cell</source><year>2019</year><volume>176</volume><fpage>998</fpage><lpage>1013</lpage><comment>e16</comment>
<pub-id pub-id-type="pmid">30712876</pub-id>
</element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><name><surname>Harmon</surname><given-names>C</given-names></name><name><surname>Zaborowski</surname><given-names>A</given-names></name><name><surname>Moore</surname><given-names>H</given-names></name><name><surname>St Louis</surname><given-names>P</given-names></name><name><surname>Slattery</surname><given-names>K</given-names></name><name><surname>Duquette</surname><given-names>D</given-names></name><etal/><article-title>gammadelta T cell dichotomy with opposing cytotoxic and wound healing functions in human solid tumors</article-title><source>Nat Cancer</source><year>2023</year><volume>4</volume><fpage>1122</fpage><lpage>37</lpage>
<pub-id pub-id-type="pmid">37474835</pub-id>
</element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><name><surname>Yan</surname><given-names>W</given-names></name><name><surname>Dunmall</surname><given-names>LSC</given-names></name><name><surname>Lemoine</surname><given-names>NR</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><article-title>The capability of heterogeneous gammadelta T cells in cancer treatment</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1285801</fpage>
<pub-id pub-id-type="pmid">38077392</pub-id>
</element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><name><surname>Bouwman</surname><given-names>AC</given-names></name><name><surname>van Daalen</surname><given-names>KR</given-names></name><name><surname>Crnko</surname><given-names>S</given-names></name><name><surname>Ten Broeke</surname><given-names>T</given-names></name><name><surname>Bovenschen</surname><given-names>N</given-names></name><article-title>Intracellular and Extracellular Roles of Granzyme K</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><fpage>677707</fpage>
<pub-id pub-id-type="pmid">34017346</pub-id>
</element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><name><surname>Lei</surname><given-names>Y</given-names></name><name><surname>Takahama</surname><given-names>Y</given-names></name><article-title>XCL1 and XCR1 in the immune system</article-title><source>Microbes Infect</source><year>2012</year><volume>14</volume><fpage>262</fpage><lpage>7</lpage>
<pub-id pub-id-type="pmid">22100876</pub-id>
</element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><name><surname>Hoekstra</surname><given-names>ME</given-names></name><name><surname>Slagter</surname><given-names>M</given-names></name><name><surname>Urbanus</surname><given-names>J</given-names></name><name><surname>Toebes</surname><given-names>M</given-names></name><name><surname>Slingerland</surname><given-names>N</given-names></name><name><surname>de Rink</surname><given-names>I</given-names></name><etal/><article-title>Distinct spatiotemporal dynamics of CD8(+) T cell-derived cytokines in the tumor microenvironment</article-title><source>Cancer Cell</source><year>2024</year><volume>42</volume><fpage>157</fpage><lpage>67</lpage><comment>e9</comment>
<pub-id pub-id-type="pmid">38194914</pub-id>
</element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><name><surname>Zhang</surname><given-names>XF</given-names></name><name><surname>Zhang</surname><given-names>XL</given-names></name><name><surname>Wang</surname><given-names>YJ</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>ML</given-names></name><name><surname>Liu</surname><given-names>XY</given-names></name><etal/><article-title>The regulatory network of the chemokine CCL5 in colorectal cancer</article-title><source>Ann Med</source><year>2023</year><volume>55</volume><fpage>2205168</fpage>
<pub-id pub-id-type="pmid">37141250</pub-id>
</element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><name><surname>Mempel</surname><given-names>TR</given-names></name><name><surname>Lill</surname><given-names>JK</given-names></name><name><surname>Altenburger</surname><given-names>LM</given-names></name><article-title>How chemokines organize the tumour microenvironment</article-title><source>Nat Rev Cancer</source><year>2024</year><volume>24</volume><fpage>28</fpage><lpage>50</lpage>
<pub-id pub-id-type="pmid">38066335</pub-id>
</element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Ge</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><etal/><article-title>MED1 Downregulation Contributes to TGFbeta-Induced Metastasis by Inhibiting SMAD2 Ubiquitination Degradation in Cutaneous Melanoma</article-title><source>J Invest Dermatol</source><year>2022</year><volume>142</volume><fpage>2228</fpage><lpage>37</lpage><comment>e4</comment>
<pub-id pub-id-type="pmid">35131256</pub-id>
</element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Hou</surname><given-names>LK</given-names></name><name><surname>Chi</surname><given-names>JR</given-names></name><name><surname>Mao</surname><given-names>JF</given-names></name><name><surname>Xia</surname><given-names>L</given-names></name><etal/><article-title>Serum deprivation response inhibits breast cancer progression by blocking transforming growth factor-beta signaling</article-title><source>Cancer Sci</source><year>2016</year><volume>107</volume><fpage>274</fpage><lpage>80</lpage>
<pub-id pub-id-type="pmid">26749136</pub-id>
</element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><name><surname>Hartwig</surname><given-names>T</given-names></name><name><surname>Montinaro</surname><given-names>A</given-names></name><name><surname>von Karstedt</surname><given-names>S</given-names></name><name><surname>Sevko</surname><given-names>A</given-names></name><name><surname>Surinova</surname><given-names>S</given-names></name><name><surname>Chakravarthy</surname><given-names>A</given-names></name><etal/><article-title>The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2</article-title><source>Mol Cell</source><year>2017</year><volume>65</volume><fpage>730</fpage><lpage>42</lpage><comment>e5</comment>
<pub-id pub-id-type="pmid">28212753</pub-id>
</element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><name><surname>Johnstone</surname><given-names>RW</given-names></name><name><surname>Frew</surname><given-names>AJ</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name><article-title>The TRAIL apoptotic pathway in cancer onset, progression and therapy</article-title><source>Nat Rev Cancer</source><year>2008</year><volume>8</volume><fpage>782</fpage><lpage>98</lpage>
<pub-id pub-id-type="pmid">18813321</pub-id>
</element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><name><surname>Philips</surname><given-names>RL</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Cheon</surname><given-names>H</given-names></name><name><surname>Kanno</surname><given-names>Y</given-names></name><name><surname>Gadina</surname><given-names>M</given-names></name><name><surname>Sartorelli</surname><given-names>V</given-names></name><etal/><article-title>The JAK-STAT pathway at 30: Much learned, much more to do</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>3857</fpage><lpage>76</lpage>
<pub-id pub-id-type="pmid">36240739</pub-id>
</element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><name><surname>Tehrani</surname><given-names>SS</given-names></name><name><surname>Mikulski</surname><given-names>P</given-names></name><name><surname>Abdul-Zani</surname><given-names>I</given-names></name><name><surname>Mata</surname><given-names>JF</given-names></name><name><surname>Siwek</surname><given-names>W</given-names></name><name><surname>Jansen</surname><given-names>LE</given-names></name><article-title>STAT1 is required to establish but not maintain interferon-gamma-induced transcriptional memory</article-title><source>EMBO J</source><year>2023</year><volume>42</volume><fpage>e112259</fpage>
<pub-id pub-id-type="pmid">37272165</pub-id>
</element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><name><surname>Tadros</surname><given-names>HJ</given-names></name><name><surname>Life</surname><given-names>CS</given-names></name><name><surname>Garcia</surname><given-names>G</given-names></name><name><surname>Pirozzi</surname><given-names>E</given-names></name><name><surname>Jones</surname><given-names>EG</given-names></name><name><surname>Datta</surname><given-names>S</given-names></name><etal/><article-title>Meta-analysis of cardiomyopathy-associated variants in troponin genes identifies loci and intragenic hot spots that are associated with worse clinical outcomes</article-title><source>J Mol Cell Cardiol</source><year>2020</year><volume>142</volume><fpage>118</fpage><lpage>25</lpage>
<pub-id pub-id-type="pmid">32278834</pub-id>
</element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Miyata</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Sha</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><etal/><article-title>Bi-allelic DNAH8 Variants Lead to Multiple Morphological Abnormalities of the Sperm Flagella and Primary Male Infertility</article-title><source>Am J Hum Genet</source><year>2020</year><volume>107</volume><fpage>330</fpage><lpage>41</lpage>
<pub-id pub-id-type="pmid">32619401</pub-id>
</element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><name><surname>Papadopoulou</surname><given-names>M</given-names></name><name><surname>Sanchez Sanchez</surname><given-names>G</given-names></name><name><surname>Vermijlen</surname><given-names>D</given-names></name><article-title>Innate and adaptive gammadelta T cells: How, when, and why</article-title><source>Immunol Rev</source><year>2020</year><volume>298</volume><fpage>99</fpage><lpage>116</lpage>
<pub-id pub-id-type="pmid">33146423</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="F1"><label>Figure 1</label><caption><p>Schematic flowchart of the study.</p></caption><graphic xlink:href="jcav16p1167g001" position="float"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold> Tracking and annotating &#x003b3;&#x003b4; T cells from single-cell transcriptome data of lung adenocarcinoma.</bold> (A) Uniform Manifold Approximation and Projection (UMAP)based (left) and t-Distributed Stochastic Neighbor Embedding (t-SNE)-based (right) dimensionality reduction map. The cell cluster annotations are marked with different colors. (B) The expression levels of cell marker genes in different cell cluster annotations are demonstrated by dotplot. The Y-axis represents the identity of cell cluster, the X-axis indicates the names of marker genes. The color of the dots represents the average expression level of the gene in the cell clusters. The size of the dots represents the proportion of gene expression in the corresponding cell clusters. Tem, effector memory T cells; Trm, tissue-resident memory T cells; Texh, exhausted T cells; Prolif, proliferating markers; Treg, regulatory T cells; pDC, plasmacytoid dendritic cell; NK, natural killer cell; Endothelial, endothelial cells; Epithelial, epithelial cells.</p></caption><graphic xlink:href="jcav16p1167g002" position="float"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold> Dynamic developmental transition of &#x003b3;&#x003b4; T cells and their interactions with other cells components in the tumor microenvironment of lung adenocarcinoma.</bold> (A-B) Pseudotime trajectory analysis showing the dynamic developmental transition of &#x003b3;&#x003b4; T cells. Cells are colored by clusters (A) and pseudotime (B), illustrating distinct cellular states and transitions along the developmental trajectory. (C) The UMAP plot illustrates the manually defined dichotomous states of &#x003b3;&#x003b4; T cells. (D) Dynamic gene expression of the genes of interest along the cellular trajectory developmental timeline. (E) Circular plot displaying the communication of the INF-&#x003b3; signaling pathway between different cell components. (F) Dot plot illustrating the interactions of &#x003b3;&#x003b4; T cells to other cells.</p></caption><graphic xlink:href="jcav16p1167g003" position="float"/></fig><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold> Increased infiltration of &#x003b3;&#x003b4; T cells is associated with better survival, somatic mutations, and decreased malignant tumor phenotypes.</bold> (A) Kaplan-Meier curves describing overall survival (OS) in lung adenocarcinoma patients with different infiltration levels of &#x003b3;&#x003b4; T cell infiltration. (B) Forest plot showing statistically significant differences in somatic single nucleotide variants (SNVs) between patients with high and low &#x003b3;&#x003b4; T cell infiltration. OR &#x0003e; 1 indicates a higher frequency of SNVs in the high &#x003b3;&#x003b4; T cell infiltration group, OR &#x0003c; 1 indicates a higher frequency in the low infiltration group, and OR = 1 indicates similar SNV frequencies between the two groups. (C) Bar chart displaying the mutation frequencies in two groups. (D-I) Significant enrichment of representative tumor malignancy pathways in patients with low &#x003b3;&#x003b4; T cell infiltration based on hallmark gene set (D, <italic>KRAS</italic> signaling; E, <italic>E2F</italic> targets; F, G2M checkpoint; G, <italic>NOTCH</italic> signaling; H, TGF-&#x003b2; signaling; I, angiogenesis).</p></caption><graphic xlink:href="jcav16p1167g004" position="float"/></fig><fig position="float" id="F5"><label>Figure 5</label><caption><p><bold> High &#x003b3;&#x003b4; T cell infiltration is associated with greater benefits from immunotherapy.</bold> (A-B) Bar chart and stacked plot indicating TIDE data on responsiveness to immunotherapy. (C) Violin plot comparing TIDE scores between high- and low- &#x003b3;&#x003b4; T cells infiltration abundance groups. (D) Scatter plot of EaSIer scores in high- and low- &#x003b3;&#x003b4; T cells infiltration abundance groups. The bar chart and Z-score scatter plot revealing the contribution weights to immunotherapy of different immune cells (E) and biological pathways (F). The scatter plot shows a significant positive correlation between the expression levels of the top 30 genes characterizing &#x003b3;&#x003b4; T cells and the expression levels of <italic>CTLA4</italic> (G), <italic>LAG3</italic> (H), <italic>PDCD1</italic> (I), and C<italic>D273</italic> (J).</p></caption><graphic xlink:href="jcav16p1167g005" position="float"/></fig><fig position="float" id="F6"><label>Figure 6</label><caption><p><bold> A LASSO linear regression model was established based on radiomics analysis of CT images, serving as a non-invasive strategy to estimate &#x003b3;&#x003b4; T cells.</bold> (A) Schematic diagram illustrating the radiomics analysis process. (B) Example of the ROIs (Region of Interest) segmentation in 3D Slicer software. (C) Coefficient distribution of variables in LASSO regression. Each curve represents radiomic features filtered by Pearson correlation. The y-axis indicates their corresponding coefficients in the LASSO regression. The top value represents the number of radiomic features selected through Pearson correlation and included in the LASSO regression model. (D) Parameter tuning plot in Least Absolute Shrinkage and Selection Operator (LASSO) regression. The top value has the same meaning as shown in panel C. Correlation between the abundance of &#x003b3;&#x003b4; T cells measured by transcriptomics and the fitted values (predicted &#x003b3;&#x003b4; T cell abundance) from the linear regression radiomic model in the training set (E) and test set (F). The gray area represents the range of 95% confidence intervals (CI).</p></caption><graphic xlink:href="jcav16p1167g006" position="float"/></fig></floats-group></article>